#SPRY ARS Pharmaceuticals 2024 Q3 Earnings: ARS Pharmaceuticals reported a net loss with strategic global expansion and strong cash position in Q3 2024.

- Revenue: $2.1 million

- EPS: -$0.20 vs. forecast -$0.18 (3 analysts)

- Net Loss: $19.1 million

- Cash Position: $349.6 million pro forma

- Global Expansion: neffy in Europe and Canada

If you enjoyed this video, please like, subscribe, and hit the notification bell to stay updated with our latest stock analysis and market insights. Leave a comment below with your thoughts on the video, and any other stocks you'd like us to cover.

*Check out our latest videos on more earnings:*

- #LOAR Loar Holdings 2024 Q3 Earnings: [ Ссылка ]

- #GFF Griffon 2024 Q4 & Full Year Earnings: [ Ссылка ]

- #HUT Hut 8 2024 Q3 Earnings: [ Ссылка ]

- #RKLB Rocket Lab 2024 Q3 Earnings: [ Ссылка ]

- #OUT OUTFRONT Media 2024 Q3 Earnings: [ Ссылка ]

свернуть